Haleon plc (LON:HLN - Get Free Report) insider Alan Stewart acquired 33,923 shares of the business's stock in a transaction on Wednesday, November 6th. The stock was acquired at an average price of GBX 368 ($4.79) per share, with a total value of £124,836.64 ($162,505.39).
Haleon Stock Up 0.4 %
LON HLN opened at GBX 363.30 ($4.73) on Friday. The business's fifty day simple moving average is GBX 383.61 and its 200-day simple moving average is GBX 355.08. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 54.18. The firm has a market cap of £32.84 billion, a PE ratio of 3,027.50, a P/E/G ratio of 1.49 and a beta of 0.19. Haleon plc has a 52 week low of GBX 308.37 ($4.01) and a 52 week high of GBX 400.65 ($5.22).
Wall Street Analysts Forecast Growth
Separately, Berenberg Bank upped their price target on Haleon from GBX 410 ($5.34) to GBX 447 ($5.82) and gave the company a "buy" rating in a research report on Monday, August 5th.
Get Our Latest Stock Report on HLN
Haleon Company Profile
(
Get Free Report)
📉 Warning: Market Crash Predicted - Secure Your Savings
From Behind the Markets | Ad
The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.
Take these 4 steps to protect your retirement here >>>
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
